Comparing the prognosis of esophageal adenocarcinoma with bone and liver metastases: A competing risk analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Metastatic esophageal adenocarcinoma (mEAC) patients with bone metastasis (BM) have a worse prognosis than those with liver metastasis (LM). Surgery and chemotherapy improve survival for mEAC patients.
Area Of Science
- Oncology
- Cancer Research
- Clinical Medicine
Background
- Metastatic esophageal adenocarcinoma (mEAC) presents significant challenges, with limited research on prognostic factors for patients with distant metastases.
- Approximately 50% of esophageal cancer patients are diagnosed with metastasis, highlighting the need for understanding survival predictors.
Purpose Of The Study
- To investigate and compare the prognostic impact of single bone metastasis (BM) versus single liver metastasis (LM) on overall survival (OS) and cancer-specific survival (CSS) in mEAC patients.
- To identify key prognostic factors influencing survival outcomes in mEAC.
Main Methods
- Utilized data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program database.
- Employed multivariate Cox regression, Kaplan-Meier analysis, and competing risk regression models to compare survival outcomes between BM and LM groups.
- Analyzed overall survival (OS), EAC-specific survival (CSS), and EAC-specific death (EASD).
Main Results
- In a cohort of 1,278 mEAC patients, bone metastasis (BM) was identified as a significant risk factor for poorer prognosis compared to liver metastasis (LM).
- Surgery and chemotherapy were found to be protective factors, improving both OS and CSS.
- Higher tumor grade (III-IV vs. I-II) and specific marital statuses (divorced/separated, single/unmarried) were associated with increased risk.
Conclusions
- Metastatic esophageal adenocarcinoma (mEAC) patients with bone metastasis (BM) experience a worse prognosis than those with liver metastasis (LM).
- Surgical intervention and chemotherapy demonstrate significant survival benefits for mEAC patients.
- Findings provide crucial evidence for optimizing clinical management strategies for mEAC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...